medigraphic.com

2011, Número 4

<< Anterior Siguiente >>

Rev Hematol Mex 2011; 12 (4)


Tratamiento de la leucemia mieloide crónica en fase crónica: una perspectiva mexicana

Gómez-Almaguer D, Tarín-Arzaga LC

Idioma: Español
Referencias bibliográficas: 63
Paginas: 267-275
Archivo PDF: 105.26 Kb.


RESUMEN

El tratamiento de la leucemia granulocítica crónica ha evolucionado con gran rapidez: desde los inicios relativamente modernos, cuando contábamos con el busulfán, hasta pasar por la hidroxiurea, el interferón y el trasplante alogénico de células hematopoyéticas. El imatinib causó una verdadera revolución en esta enfermedad y es el medicamento más utilizado en el mundo. Existe evidencia que sugiere que algunos pacientes pueden curarse. La aparición de nuevos agentes, como: dasatinib, nilotinib o bosutinib hacen más interesante el campo de tratamiento de esta leucemia, porque son más potentes y eficaces. El trasplante no ha desaparecido, pero se utiliza en forma más selecta y con métodos no mieloablativos. En el mundo en desarrollo es necesario optimizar los recursos y, para ello, deben diseñarse estudios prospectivos para evaluar diversas alternativas adaptables a nuestra sociedad y economía.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Faderl S, Talpaz M, Estrov Z, et al. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999;131:207-219.

  2. Cortes J. Natural history and staging of chronic myelogenous leukemia. Hematol Oncol Clin N Am 2004;18:569-584.

  3. Quintas-Cardama A, Cortes JE. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 2006;81:973-988.

  4. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3334-3356.

  5. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin 2008;58:71-96.

  6. Barnes DI, Melo JV. Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia. Acta Haematol 2002;108:180-202.

  7. Hehlmann R, Heimpel H, Hasford J, et al and the German CML Study Group. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia. Prolongation of survival by hidroxiurea. Blood 1993;82:398-407.

  8. Silver RT, Woolf SH, Hehlmann R, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999;94:1517-1536.

  9. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med 1994;330:820-825.

  10. Gaziev D, Galimberti M, Polchi P, et al. Fate of chronic myeloid leukemia patients treated with allogenic bone marrow transplantation or chemotherapy and/or interferon at a single center: long term results. Bone Marrow Transplant 2002;229:1-8.

  11. Cortes J, Talpaz M, O’Brien S, et al. Suppression of cytogenetic clonal evolution with interferon alfa in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. J Clin Oncol 1998; 16:3279-3285.

  12. Baccarani M, Russo D, Rosti G, et al. Interferon-alfa for chronic myeloid leukemia. Semin Hematol 2003;40:22-33.

  13. Kantarjian HM, Giles FJ, O’Brien S, et al. Clinical course and therapy of chronic myelogenous Leukemia with interferonalpha and chemotherapy. Hematol Oncol Clin North Am 1998;12:31-80.

  14. Hochhaus A, Weisser A, La Rosee P, et al. Molecular heterogeneity in complete cytogenetic responders after interferonalpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and UK MRC CML Study Group. Blood 2000;95:62-66.

  15. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997;337:223-229.

  16. Kantarjian HM, O’Brien S, Smith TL, et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low dose cytarabine. J Clin Oncol 1999;17:284-292.

  17. Drucker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.

  18. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-145.

  19. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogeneic responses to Imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652.

  20. Hughes TP, Kaeda J, Brandford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-1432.

  21. O´Brien SG, Guihot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.

  22. Druker BJ, Guilhot F, O´brien SG, et al. Five year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417.

  23. Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myelogenous leukemia on Imatinib versus interferon alfa plus low-dose cytarabine: results from IRIS study. J Clin Oncol 2003;21:2138-2146.

  24. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European leukemia Net. Blood 2006;108:1809-1820.

  25. Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on Imatinib mesylate therapy. Blood 2003;101:3794-3800.

  26. Brandford S, Eudzki Z, Walsh S, et al. Detection of bcr-abl mutations in patients with CML treated with Imatinib is virtually always accompanied by clinical resistance, and mutations in the ATO phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;101:276-283.

  27. Sacha T, Hochhaus A, Hanfstein B, et al. ABL-kinase domain point mutation as a cause of Imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis. Leukemia Res 2003;27:1163-1166.

  28. Jabbour E, Kantajian HM, Jones D, et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009:113:2154-2160.

  29. Hochhaus A, La Rosée P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004;18: 1321-1331.

  30. Kantarjian H, Talpaz M, O’Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome- positive chronic phase chronic myeloid leukemia. Blood 2004;103:2873-2878.

  31. Aoki E, Kantarjian H, O´Brien S, et al. High-dose imatinib mesylate treatment in patients with untreated early chronic phase chronic myeloid leukemia. Blood 2004;103:2873-2878.

  32. Zonder JA, Pemberton P, Brandt H, et al. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res 2003;9:2092-2097.

  33. Talpaz M, Shah NP, Kantarjian H. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemia. N Eng J Med 2006;354:2531-2541.

  34. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109:2303.

  35. Kantarjian H, Pasquini R, Hamerschlak N. Dasatinib or highdose imatinib for chronic-phase chronic myeloid leukemia after failure first-line imatinib: a randomized phase 2 trial. Blood 2007;109:5143-5150.

  36. Cortes, J, O'Brien, S, Jones, D, et al. Efficacy of dasatinib in patients with previously untreated chronic myelogenous leukemia in early chronic phase (abstract). Blood 2007; 110:17.

  37. Shah NP, Kantarjian HM, Kim DW. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204-3212.

  38. Jabbour E, Kantarjian HM, Jones D, et al. Characteristics and outcome of chronic myeloid leucemia patients with F317L BCR-ABL kinase domain mutation alter therapy with tyrosine kinase inhibitors. Blood 2008 112:4839-4842.

  39. Kantarjian H, Shah NP, Hochhaus A, et al Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010:2260-2270.

  40. Kantarjian, H, Giles, F, Wunderle, L, et al. Nilotinib in imatinibresistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-2551.

  41. Hazarika M, Jiang X, Liu Q, et al. Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 2008; 14:5325.

  42. Giles, F, le Coutre, P, Bhalla K, et al. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who have also failed dasatinib therapy (abstract). Blood 2006;108:2170.

  43. Saglio G, Kim DG, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Eng J Med 2010;362:2251-2259.

  44. Cortes J, O'Brien S, Jabbour E, et al. Efficacy of nilotinib (AMN107) in patients with newly diagnosed, previously untreated Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase (abstract). Blood 2007;110:17a.

  45. Lima L, Bernal-Mizrachi L, Saxe D, et al. Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents and beyond. Cancer 2011;117:1245-1252.

  46. Cortes J, Kantarjian HM, Baccarani M, et al. A phase 1/2 study of SKI-606, a dual inhibitor of Src and Abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory or intolerant of imatinib. Blood 2006;108:54a.

  47. Giles FJ, Cortes JE, Jones D, et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007;109:500-502.

  48. Borthakur G, Kantarjian HM, Daley G, et al. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer 2006;106:346-352.

  49. Cortes J, Albitar M, Thomas D, et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003;101:1692-1697.

  50. Gratwohl A, Brand R, Apperley I, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, log-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006;91:513-521.

  51. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998;352:1087-1092.

  52. Passweg JR, Walker I, Sobocinski KA, et al. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia receiving allogeneic haematopoietic stem cell transplants. Br J Haematol 2004;125:613-620.

  53. Or R, Shapira MY, Resnick I, et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003;101:441-445.

  54. Ruiz-Argüelles GJ, Tarin-Arzaga LC, Gonzalez-Carrillo. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs? Bone Marrow Transpl 2008;42:23-28.

  55. Kantarjan H, Cortes J, Guilhot F, et al. Diagnosis and management of chronic myeloid leukemia. A survey of American and European practice. Cancer 2007;109:1365-1374.

  56. Aguayo A, García Alvarez E, Cazares-Ordoñez Y, et al. Chronic myeloid leukemia: a clinicoepidemiologic and therapeutic description of a single institution in Mexico city. Clin Leuk 2008;2:261-266.

  57. Rajappa S, Varadpande L, Paul T, et al. Imatinib mesylate in early phase chronic myeloid leukemia: Experience from a developing country. Leukemia & Lymphoma 2008;49(3):554-558.

  58. Pavlovsky C, Fernández I, Pavlovsky M, et al. Diez años de seguimiento y monitoreo de 87 pacientes con leucemia mieloide crónica tratados con inhibidores de cinasa de tirosina: experiencia en FUNDALEU, Buenos Aires, Argentina. Rev Hematol Mex 2011;12:11-16.

  59. Aziz Z, Iqbal J, Akram M, et al. Treatment of chronic myeloid leukemia in the imatinib era. Perspective from a developing country. Cancer 2007;109:1138-1144.

  60. Kim DW, Banavali SD, Bunworasate U, et al. Chronic myeloid leukemia in the Asia-Pacific region:current practice, challenges and opportunities in the targeted therapy era. Leukemia research 2010;

  61. Cortes J, De Saouza C, Ayala-Sanchez M, et al. Current patient management of chronic myeloid leukemia in Latin America. Cancer 2010;116:4991-5000.

  62. Mahon FX, Réa D, Guilhot J et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective multicentre Stop imatinib ( STIM) trial. Lancet Oncol 2010; 11:1029-1035.

  63. Ross DM, Grigg A, Schwarer A, et al. The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR, and any relapses occur early. Blood 2008;112( suppl 1) 402-403.




2020     |     www.medigraphic.com